Pharmaceutical

Boehringer Ingelheim advances weight loss drug to Phase III trials

Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.

Aug 18, 2023 - 20:00
Boehringer Ingelheim advances weight loss drug to Phase III trials
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
Read the original article

Tags:

Previous Article

AbbVie achieves win for migraine prevention drug Aquipta in Europe

Next Article

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why many more people are lining up for a flu shot than a Covid vaccine

Why many more people are lining up for a flu shot than ...

Jan 22, 2024

Avalyn raises $175m in funding to develop inhaled IPF drugs

Avalyn raises $175m in funding to develop inhaled IPF d...

Sep 27, 2023

STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles

STAT+: Pharmalittle: Drugmakers raise prices, pharmacie...

Jan 2, 2024